Yahoo Finance 6/21/13
Insider Transactions Reported
Date Insider Shares Cost
Jun 4, 2013 BAKER FELIX 872,585 . 12,670,0002
Jun 3, 2013 BAKER FELIX 699,776 10,119,0002
Jun 2, 2013 BAKER FELIX 767,953 10,782,000
This was copied and pasted from ACAD Homepage Website:
We hold worldwide rights to pimavanserin and have established a patent portfolio, which includes
numerous issued patents covering pimavanserin in the United States, Europe and several additional countries.
We believe that pimavanserin also has the potential to address a range of other neurological and psychiatric disorders that are under served by currently available anti psychotics and represent large unmet medicalneeds. This may include treatment for psychoses associated with other neurological disorders, including Alzheimer’s disease, and as a co-therapy for schizophrenia.
look at acad now
you don't think Lilly carries more than one kind of drug for each illness? Broaden your horizions man.
run- up will be massive upside
Just Read Article , Great For People New bto ACAD.
Acadia Has A Silver Lining In Its Playbook Seeking Alpha
Jun 5 2013,
In short, Acadia Pharmaceuticals is showing great promise in its pimavanserin trials. And, biotech fund
manager activity and FDA actions are validating my theory that pimavanserin is going to be a blockbusterdrug.